| Literature DB >> 18479914 |
Mark T Bilodeau1, Adrienne E Balitza, Jacob M Hoffman, Peter J Manley, Stanley F Barnett, Deborah Defeo-Jones, Kathleen Haskell, Raymond E Jones, Karen Leander, Ronald G Robinson, Anthony M Smith, Hans E Huber, George D Hartman.
Abstract
A series of naphthyridine and naphthyridinone allosteric dual inhibitors of Akt1 and 2 have been developed. These compounds have been optimized to have potent dual activity against the activated kinase as well as the activation of Akt in cells. One molecule in particular, compound 17, has potent inhibitory activity against Akt1 and 2 in vivo in a mouse lung and efficacy in a tumor xenograft model.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18479914 DOI： 10.1016/j.bmcl.2008.04.074
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823